London's Court of Appeal on Friday struck down a case filed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), in a bid to ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...

Throughout the last three months, 11 analysts have evaluated BioNTech (NASDAQ:BNTX), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent.

BioNTech (NASDAQ:BNTX) is scheduled to announce Q2 earnings results on Monday, August 4th, before market open. The consensus EPS Estimate is -$1.65 (+50.9% Y/Y) and the consensus Revenue Estimate is ...

US mRNA specialist Moderna has announced that the UK Court of Appeal has upheld the validity of its EP'949 patent.

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorizations ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages including the XFG and NB.1.8.1 variants1 compared to 2024-20 ...

Both companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types.

Last month, Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and co-commercialization of the latter’s investigational ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the European Medicines Agency's (EMA) Committee for ...